New Drug Promises Relief From Chronic Migraine

New Drug Promises Relief From Chronic Migraine


AND EFFECTIVE FOR THE CRIPPLING PAIN. MIGRAINE HEADACHES. ONE OF THEM IS JUST APPROVED BY THE FDA. CBS 2’S DR. MAX GOMEZ REPORTS. MY MIGRAINES ARE PRECEDED BY AN AURA, UM, IT’S LIKE A, A FLASHING LIGHT, UM, YOU KNOW, SPOTS IN FRONT OF YOUR EYES, SOMETIMES YOU — YOUR PERIPHERAL VISION IS CUT OFF. Reporter: THAT WAS JUST THE START OF MICHAEL JOHNSON’S MIGRAINES. SIX TO EIGHT DAYS A MONTH, THE AURA WOULD PROGRESS TO DEBILITATING HEADACHE PAIN THAT WOULD LAST FOR HOURS. I REALLY WOULD HAVE TO LAY DOWN IN A DARKENED ROOM, UM, EVEN AFTER I TOOK SOMETHING, YOU KNOW, UM, IT WAS VERY, VERY HARD TO — TO EVEN SIT UP. Reporter: WHILE THERE ARE A VARIETY OF MIGRAINE DRUGS ON THE MARKET, THEY CAN HAVE DIFFICULT SIDE EFFECTS AND TAKE TIME TO WORK AND ADJUST THE DOSAGE. BUT A HEADACHE NEUROLOGIST SAYS THERE’S A NEW CLASS OF DRUGS. THESE ARE TRULY THERAPEUTIC BREAKTHROUGHS FOR MIGRAINE BECAUSE THE DRUGS DELIVER HIGH LEVELS OF THERAPEUTIC BENEFITS FOR MANY PEOPLE WITH VERY FEW SIDE EFFECTS. AND FINALLY, THE BENEFITS COME ON VERY RAPIDLY. Reporter: THE NEW DRUGS TARGET A CHEMICAL AND RECEPTOR ON BRAIN CELLS CALLED CG RP THAT DILATE BLOOD VESSELS INVOLVED IN PAIN SENSITIVITY. SON ANTIBODIES TIE IT UP, OTHERS BLOCK THE RECEPTOR FOR CGRP ON NERVE CELLS. THE FIRST OF THESE NEW DRUGS IS CALLED — IT WILL BE AVAILABLE IN AN AUTO INJECTOR SIMILAR TO EpiPENS THAT A MIGRAINE PATIENT WOULD INJECT ONCE A MONTH. THEY DON’T WORK FOR EVERYBODY, BUT IN HALF OF PEOPLE OR MORE THAN THAT, DEPENDING ON THE STUDY, AT LEAST HALF THE ATTACKS ARE PREVENTED. Reporter: MICHAEL JOHNSON HAS BEEN IN THE CLINICAL TRIAL FOR FOUR YEARS. HE SAYS THE DRUG HAS BEEN A LIFE CHANGER FOR HIM. NOT ONLY DO I HAVE LESS MIGRAINES BUT THEY ARE LESS SEVERE. BEFORE THEY WERE MODERATE TO SEVERE. NOW IT’S MORE MILD TO MODERATE. Reporter: THE DRUG IS MEANT AS AN INJECTABLE PREVENTATIVE

1 comment on “New Drug Promises Relief From Chronic Migraine

Leave a Reply

Your email address will not be published. Required fields are marked *